Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 1,900 shares of the stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $7.00, for a total transaction of $13,300.00. Following the completion of the sale, the chief technology officer now owns 6,008,502 shares of the company's stock, valued at approximately $42,059,514. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Ming Yan also recently made the following trade(s):
- On Monday, March 18th, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The shares were sold at an average price of $6.77, for a total transaction of $135,400.00.
Cytek Biosciences Stock Up 0.8 %
Shares of Cytek Biosciences stock traded up $0.05 during mid-day trading on Thursday, hitting $6.30. The stock had a trading volume of 354,777 shares, compared to its average volume of 722,997. The firm has a market cap of $824.17 million, a P/E ratio of -69.99 and a beta of 1.37. The firm has a 50-day moving average of $7.47 and a two-hundred day moving average of $7.06. Cytek Biosciences, Inc. has a 12-month low of $3.80 and a 12-month high of $12.31.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on CTKB shares. The Goldman Sachs Group increased their price target on shares of Cytek Biosciences from $9.00 to $10.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Stephens started coverage on shares of Cytek Biosciences in a research note on Thursday, December 14th. They issued an "overweight" rating and a $9.00 price target for the company. Finally, Piper Sandler dropped their price target on shares of Cytek Biosciences from $11.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, March 6th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.00.
Read Our Latest Stock Analysis on CTKB
Hedge Funds Weigh In On Cytek Biosciences
A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in shares of Cytek Biosciences by 222.0% during the 3rd quarter. Royal Bank of Canada now owns 2,074 shares of the company's stock worth $30,000 after purchasing an additional 1,430 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Cytek Biosciences by 16.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,009 shares of the company's stock worth $85,000 after purchasing an additional 1,445 shares during the period. Metropolitan Life Insurance Co NY boosted its position in shares of Cytek Biosciences by 31.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock worth $69,000 after purchasing an additional 1,536 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Cytek Biosciences by 7.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,534 shares of the company's stock worth $198,000 after purchasing an additional 1,558 shares during the period. Finally, Credit Suisse AG boosted its position in shares of Cytek Biosciences by 3.5% during the 3rd quarter. Credit Suisse AG now owns 47,115 shares of the company's stock worth $694,000 after purchasing an additional 1,604 shares during the period. Hedge funds and other institutional investors own 69.46% of the company's stock.
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
